TargetMol

Mirabegron

Product Code:
 
TAR-T1671
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1671-1mg1mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1671-2mg2mg£106.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1671-5mg5mg£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1671-1mL1 mL * 10 mM (in DMSO)£131.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1671-10mg10mg£164.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1671-25mg25mg£234.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1671-50mg50mg£367.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1671-100mg100mg£497.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1671-500mg500mg£1,018.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Mirabegron is a beta-3 adrenergic agonist that is used for treatment of overactive bladder syndrome.
CAS:
223673-61-8
Formula:
C21H24N4O2S
Molecular Weight:
396.51
Pathway:
GPCR/G Protein; Neuroscience
Purity:
0.9975
SMILES:
Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1
Target:
Adrenergic Receptor

Documents

References

1. Takasu T, et al. J Pharmacol Exp Ther, 2007, 321(2), 642-647. 2. Takusagawa S, et al. Xenobiotica, 2012, 42(12), 1187-1196. 3. Aizawa N, et al. Eur Urol, 2012, 62(6):1165-1173. 4. Hatanaka T, et al. Naunyn Schmiedebergs Arch Pharmacol, 2013, 386(1), 71-78.